|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Division of Hematology, Department of
Medicine, Jichi Medical School, Tochigi; Pharmaceutical Development
Laboratory, Kirin Brewery, Gunma; Center for Tsukuba Advanced Research
Alliance and Institute of Basic Medical Sciences, University of
Tsukuba; Department of Molecular Oncology, Biomedical Research Center,
Osaka University Medical School; and Laboratory of Environmental
Biology, Hokkaido University School of Medicine, Sapporo, Japan.
The signal transducer and activator of transcription 3 (Stat3), a member of the Stat family of proteins, is commonly activated by thrombopoietic cytokines including thrombopoietin (TPO), interleukin (IL)-6, and interleukin-11. This finding strongly suggested that Stat3
has an important role in megakaryopoiesis and thrombopoiesis. To
clarify the functional role of Stat3 in in vivo megakaryopoiesis and
thrombopoiesis, we generated transgenic mice overexpressing a
dominant-negative Stat3, Stat3F, to suppress the function of endogenous
Stat3. To accomplish the selective expression of Stat3F in
megakaryocytic lineage cells, we used the regulatory gene region of
GATA-1 transcription factor selectively expressed in megakaryocytic and
erythroid lineage cells. Two independent transgenic (Tg) mice lines
were established. It was confirmed by Western blotting analysis that
Stat3F proteins were highly expressed in the platelets from the Tg
mice. In addition, it was found that Stat3 activation induced by TPO
stimulation was drastically suppressed in these Tg mice compared with
littermates. These findings indicate that Stat3F works well in the Tg
mice. Platelet counts were within the normal range in steady-state
conditions and were recovered normally from transient thrombocytopenia
induced by antiplatelet serum injection. Interestingly, the platelet
recovery from myelosuppression after 5-fluorouracil treatment was
significantly delayed in the Tg mice. Collectively, our results
strongly suggest that Stat3 plays an important role in the early stage
of megakaryopoiesis, presumably through the expansion of
megakaryocytic progenitor cells.
(Blood. 2002;99:3220-3227) Megakaryopoiesis and thrombopoiesis are skillfully
orchestrated with various thrombopoietic cytokines, including
interleukin (IL)-3, stem cell factor (SCF), IL-6, IL-11, and
thrombopoietin (TPO).1-5 In the early stage of
megakaryocytic development, these cytokines support the growth of
immature megakaryocytic progenitor cells as megakaryocyte
colony-stimulating factors. Subsequently, some of these cytokines also
promote megakaryocytic differentiation and platelet production as
megakaryocyte potentiator or thrombopoiesis-stimulating factors.
The action of cytokines is mediated by the activation of their cognate
receptors and downstream signal transduction pathways, including
protein kinase C, phospholipase C- Although Stat 3 knockout mice have already been established, these mice
showed embryonic lethality at E6.5 days before the onset of
hematopoiesis.16 Therefore, an alternative approach is
required for examining the Stat3 function in in vivo megakaryopoiesis and thrombopoiesis.17,18 To overcome this problem, we used transgenic (Tg) constructs in which the expression of a
dominant-negative form of Stat3, Stat3F, is controlled by the GATA-1
regulatory gene elements, because GATA-1 expression is restricted to
megakaryocytes and erythroid cells.19,20 In this study, we
established the Tg mice selectively expressing Stat3F in megakaryocytic
lineage cells. Using these Tg mice, we examined the in vivo function of Stat3 in megakaryocytic development, platelet production, and platelet
function. Our results suggest that Stat3 activation may be required for
promoting the expansion of megakaryocytic progenitor cells.
Generation of transgenic mice
Preparation of platelets
Measurement of platelet aggregation Platelet aggregation using PPACK (final concentration, 40 mM)-PRP was measured using an aggregometer (Hema Tracer model 601; Niko Bio Science, Tokyo, Japan) with continuous stirring (1000 rpm), as previously described.22Real-time quantitative PCR Real-time quantitative PCR was performed according to the standard methods using ABI prism 770 with SYBR Green PCR and RT-PCR reagents (Applied Biosystems, Foster City, CA). For the internal control, we used GAPDH forward and reverse primers included in the GAPDH Control Reagents Kit (Applied Biosystems).Reverse transcription-PCR Total cellular RNA was extracted from the spleens of 4-month-old mice using the RNeasy Midi Kit (QIAGEN, Valencia, CA) and was subjected to reverse transcription (RT)-PCR using the mRNA Selective PCR Kit (Takara Shuzo, Shiga, Japan). Primers used for RT-PCR were the same as those used in the screening.Western blot analysis Washed platelets were prepared from Tg mice and control mice as previously described.23 After incubation with or without TPO for 10 minutes, platelets were lysed for immunoprecipitation using sufficient amounts of anti-Stat3 antibodies to immunoprecipitate endogenous Stat3. Immunoprecipitated proteins were analyzed on 7.5% polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. Blots were incubated with the appropriate concentrations of primary antibodies, including antiphosphotyrosine monoclonal antibody PY20 (Transduction Laboratories, Lexington, KY) and an antibody against Stat3, and then were visualized using the enhanced chemiluminescence detection kit (ECL Western Blotting Analysis System; Amersham Pharmacia Biotech, Buckinghamshire, England).Hematologic analysis Orbital plexus blood was collected from the anesthetized mice, and peripheral blood white blood cell count, hematocrit, concentration of hemoglobin, and platelet counts were determined using Sysmex F820 (Sysmex GmbH Europe, Hamburg, Germany).In vitro colony assay For megakaryocyte colony-forming unit (CFU-Meg) assay, bone marrow cells were harvested from mice by flushing the femoral contents with -modified minimum essential medium. Marrow cells (1 × 105) were cultured with MegaCult-C media (StemCell
Technologies, Vancouver, Canada) in the presence of 10 ng/mL
recombinant mouse IL-3 (Kirin Brewery), 20 ng/mL recombinant human IL-6
(Kirin Brewery), and 50 ng/mL recombinant human TPO (Kirin Brewery)
according to the instruction manual. After culturing for 7 days, the
colonies formed were stained with acetylcholine esterase (AChE)
according to the method described by Dr C. W. Jackson.24 CFU-Meg-derived colonies were defined as
colonies with at least 3 megakaryocytes.25
Histologic analysis Samples of the femur and spleen were removed from normal and Tg mice after they were killed. Samples were fixed in formalin and embedded in paraffin, cut into 4-µM sections, and stained with hematoxylin-eosin.Administration of thrombopoietin TPO (30 µg/kg; PEG-rHUMGDF) was injected intraperitoneally once daily into Stat3F Tg mice and normal littermates for 5 days, according to the methods described elsewhere.26 After TPO treatment, platelet numbers were determined at the indicated time points.5-Fluorouracil administration After intravenous injection of a single dose of 5-fluorouracil (5-FU; 150 µg/kg) to the wild-type littermates and the Stat3F Tg mice, blood analysis was sequentially performed as described above at days 0, 5, 10, 15, and 20.Antiplatelet serum administration One hundred microliters of a 1:20 dilution of rabbit antimouse platelet serum (Inter-Cell Technologies, Hopewell, NJ) was injected intraperitoneally into the wild-type and Stat3F Tg mice. The number of platelets was counted at the indicated time points.Establishment of Stat3F-expressing UT-7/TPO cells UT-7/TPO cells were grown in liquid culture with Iscoves modified Dulbecco medium containing 10% fetal calf serum and 10 ng/mL TPO.11 Stat3F cDNA was introduced into the UT-7/TPO cells by lipofection, and cell lines expressing Stat3F were established as previously described.Luciferase assay Luciferase assay was performed with the reporter construct that contains 4 copies of the acute-phase response element (APRE), which is transactivated by Stat3, in front of the minimal jun-B promoter linked to the luciferase gene (4XAPREluc).
Stat3F works as a dominant-negative mutant in thrombopoietin signaling In our previous study, we demonstrated that Stat3F, in which tyrosine residue 705 was replaced by phenylalanine, works as a dominant-negative regulator in IL-6 and granulocyte macrophage-colony-stimulating factor signaling.27,28 To confirm whether this mutant can inhibit Stat3 function in TPO signaling, we introduced the reporter construct containing Stat3-responsive elements with or without Stat3F cDNA into UT-7/TPO cells and then performed a luciferase assay. As shown in Figure 1A, Stat3F significantly inhibited the reporter activation in response to TPO. Furthermore, the UT-7/TPO cells expressing Stat3F showed a clearly reduced-growth response to TPO. These results support the notion that Stat3F works as a dominant-negative regulator in TPO signaling.
Generation of transgenic mice selectively expressing Stat3F in megakaryocytic lineage cells To investigate the function of Stat3 in in vivo megakaryopoiesis, we generated mice selectively bearing the dominant-negative form of Stat3 in the megakaryocytic and erythroid cells. Previous studies demonstrated that this GATA-1 gene regulatory region is required and sufficient for lineage-specific expression of GATA-1 in primitive and definitive erythropoiesis.21,29 It was also reported that Tg mice generated by the introduction of the green fluorescent protein (GFP) gene under the control of this GATA-1 gene regulatory cassette, named IE3.9int, showed selective expression of GFP in the erythroid and the megakaryocytic lineage cells.21 Based on these observations, we inserted Stat3F into the IE3.9int cassette (Figure 2A) and introduced the Stat3F transgene into fertilized eggs and generated 2 independent Tg mice lines. Real-time quantitative PCR revealed that each Tg line contained an equal number of transgenes (data not shown). The expression of the transgene was monitored by mRNA-selective RT-PCR methods (Figure 2B). In addition, we confirmed by Western blotting that Stat3F proteins were overexpressed in platelets derived from the Tg mice (Figure 2C). To confirm whether Stat3F actually inhibited in vivo Stat3 activation, we examined whether Stat3 is tyrosine phosphorylated by TPO stimulation in the platelets of the Tg mice. As shown in Figure 2C, TPO rapidly induced the tyrosine phosphorylation of Stat3 in the normal platelets but not in the platelets from the Tg mice. These results indicated that Stat3F works well in the Tg mice. In contrast, the expression and activation of Stat5 were not affected in the Stat3F Tg mice (data not shown).
Stat3 is dispensable for steady-state megakaryopoiesis We initially analyzed the peripheral blood cell counts of the Tg mice. As summarized in Table 1, we did not find any differences in the peripheral blood cell counts, including platelet number, between the Tg mice and normal littermates. The size of the platelets in the Tg mice was also not affected. Histologic examination demonstrated that the numbers of megakaryocytes in bone marrow and spleen were similar in both groups of mice (Figure 3). In addition, megakaryocytes of the Tg mice did not show any significant changes in nuclear morphology or lobulation. These results indicated that the activation of Stat3 in megakaryocytic cells was dispensable for steady-state megakaryopoiesis.
Numbers of CFU-Meg colonies in transgenic mice and normal littermates We analyzed the number of hematopoietic progenitors by in vitro clonal culture with bone marrow cells (Figure 4). The number of CFU-Meg per femur in the Tg mice was slightly smaller than that in the wild-type littermates, though there was no significant difference between the 2 groups (P = .11). Moreover, we compared the sizes of CFU-Meg in the 2 groups. The proportion of larger colonies containing more than 20 cells was significantly decreased in cultures from the Stat3F Tg mice than in those from the wild-type littermates (Table 2; P < .05). These results suggest that the growth activity of megakaryocytic progenitors was reduced in the Stat3F Tg mice.
Normal response to thrombopoietin in transgenic mice To confirm that the inhibition of Stat3 signaling affects TPO-induced platelet production, we injected TPO into normal (n = 6) and Tg (n = 6) mice for 5 days and then analyzed the platelet counts. As shown in Figure 5A, platelet numbers were rapidly increased after TPO injection in both groups, and the kinetics of platelet number were almost equal in both groups. We also monitored the changes in mean platelet volume (MPV). Treatment with TPO induced transient elevations of MPV level in control and Tg mice (Figure 5B).
Normal platelet recovery from antiplatelet serum-induced thrombocytopenia Next, we analyzed the recovery of platelets after antiplatelet serum-induced thrombocytopenia. It was hypothesized that the recovery from thrombocytopenia induced by such stress mainly depends on platelet production from existing megakaryocytes.30,31 Anti-GpIIb/IIIa antibodies were administrated to the Tg (n = 3) mice and normal (n = 3) littermates. Platelet numbers were monitored at the indicated time points (Figure 6). Tg mice and control mice showed severe thrombocytopenia 4 days after administration. Reduction rates of the platelets were almost the same in both groups. After nadir, the platelet counts recovered rapidly in both groups. There was no significant difference in the recovery kinetics of platelet number between the Tg mice and the normal littermates.
Delayed recovery of platelet number after myelosuppression in Stat3F transgenic mice We also analyzed the recovery of platelet number after myelosuppression induced by 5-FU treatment. 5-FU selectively kills cycling progenitor cells, including megakaryocytic progenitor cells.31,32 Therefore, this model allows us to examine the role of Stat3 in the development of megakaryocytic progenitor cells at less mature stages. 5-FU (150 µg/kg) was administrated to 6 Tg mice and 7 control mice. Platelet counts were monitored for a 20-day recovery period (Figure 7A). Tg and control mice showed a 50% reduction in platelet count by day 5. In the control mice, the platelet number had already returned to the pretreated levels at day 10. In contrast, Stat3F Tg mice exhibited a more pronounced nadir and slower recovery from thrombocytopenia. On day 10, the average platelet count was 1162 ± 412.0 × 106/mL in the wild-type littermates, whereas it was 429.0 ± 118.0 × 106/mL in the Tg mice (P < .005). We performed 5-FU treatment experiments 3 times independently; the platelet numbers of these mice at day 10 after 5-FU treatment are summarized in Figure 7B (Tg mice, n = 12; wild-type mice, n = 14). The number of platelets was significantly lower in the Tg mice group than in the wild-type group (728.1 ± 385.3 × 106/mL vs 1366.1 ± 746 × 106/mL; P < .05). After 5-FU injection some Tg mice died, presumably from bleeding. Sixty percent (9 of 15) of the Stat3F Tg mice survived, whereas 100% (15 of 15) of the wild-type mice survived 20 days after the injection of 5-FU (P < .05). To elucidate whether the slower recovery of platelet number in the Tg mice was caused by the delayed megakaryocyte development, we performed histopathologic analysis. On day 7 after 5-FU injection, numerous megakaryocytes were detected in the bone marrow and spleen of the normal littermates (Figure 8). In contrast, the numbers of megakaryocytes in the bone marrow and spleen of the Tg mice were clearly reduced (Figure 8). On day 10, the number of megakaryocytes was slightly increased in the bone marrow and spleen of the Tg mice. However, the number of megakaryocytes was still lower than in the control. We also found a significant reduction in the number of CFU-Meg per femur in the Tg mice on day 7 after 5-FU treatment (Figure 9). These results strongly suggested that Stat3 is involved in megakaryopoiesis at an early stage.
Platelet function is intact in Stat3F Tg mice Previous reports demonstrate that TPO primes platelet aggregation induced by multiple agents and that TPO activates Stat proteins in platelets. Based on these findings, we examined whether the inhibition of Stat3 affects platelet function in the Tg mice. As shown in Figure 10, the addition of TPO equally enhanced the adenosine diphosphate (ADP)-induced aggregation of platelets in the Tg mice and control mice. This result definitely indicated that Stat3 is not involved in the priming effect of TPO on ADP-induced platelet aggregation.
One of the best ways to elucidate the physiological in vivo function of Stat3 is the establishment of Stat3 gene-targeting animals. However, because of embryonic lethality,16 Stat3-deficient mice do not provide information concerning Stat3 function in in vivo megakaryopoiesis and thrombopoiesis. To overcome this problem, we established Tg mice selectively expressing a dominant-negative form of Stat3 in megakaryocytic lineage cells. Because GATA-1 is highly expressed in erythroid and megakaryocytic lineage cells,19,20 we used Tg constructs in which the expression of Stat3F is controlled by the GATA-1 regulatory gene elements. Previous studies demonstrated that the GATA-1 regulatory region, including 3.9 kb upstream of the IE exon and the first intron, are required and sufficient for lineage-specific GATA-1 expression.21,29 Tg mice with constructs in which GFP cDNA was linked to these GATA-1 regulatory elements showed the expression of GFP in erythroid and megakaryocytic lineage cells.21 In our experiments, we confirmed that Stat3F was actually expressed in the platelets of the Tg mice. Furthermore, TPO-induced Stat3 activation was highly blocked in the Tg mice. Thus, the Tg mice allowed us to analyze the function of Stat3 in in vivo megakaryopoiesis and thrombopoiesis. We initially analyzed the effect of Stat3 on steady-state megakaryopoiesis. There was no significant difference in the platelet count of peripheral blood between the Tg mice and the control mice. Furthermore, many megakaryocytes were observed in the bone marrow and spleen in the Tg mice, as in the control mice. To examine the effect of thrombopoietin on platelet production in the Tg mice, we administered TPO to the mice once a day for 5 days and analyzed the platelet production. As shown in Figure 5, the platelet counts were transiently increased in response to TPO not only in the control mice but also in the Tg mice, indicating that TPO did not affect platelet production in the Tg mice. Because enhanced platelet production after TPO injection is dependent on the maturation of pre-existing megakaryocytes,33 our data strongly suggest that Stat3 is not involved in the maturation of megakaryocytes. In addition, we found a transient increase in MPV after TPO injection in the Tg mice, as in the control mice. Given that a transient elevation of MPV level after treatment with TPO was observed as a result of the accelerated formation of demarcation membranes and the shedding of larger fragments from megakaryocytes,34 our observation indicates that TPO signals are normally transduced into the nucleus in Tg mice. Luoh et al35 previously reported that mice having the truncated form of TPO receptor produced platelets within the normal range in steady-state conditions, regardless of impaired activation of signal transduction molecules, including Stat3. Taken together with our observation, Stat3 may not be required for the maturation of megakaryocytes and platelet production in steady-state conditions. To further understand the in vivo function of Stat3 in megakaryopoiesis and thrombopoiesis, we analyzed the kinetics of recovery time of platelet production after induced thrombocytopenia. We adopted 2 methods; one was antiplatelet serum administration, and the other was 5-FU treatment. The administration of antiplatelet serum can induce a rapid decrease in platelet number without damaging the megakaryocytes and immature megakaryocytic progenitors.30,31 In this method, the recovery of platelet count is mainly dependent on the platelet production from mature megakaryocytes and the development of megakaryocytic progenitor cells. Thus, this method allows us to clarify the functional role of Stat3 in the late stage of in vivo megakaryopoiesis and platelet production. In contrast, 5-FU kills immature megakaryocytic progenitors and megakaryocytes in endomitosis.31,32 Therefore, this method allows us to examine the functional role of Stat3 in the early stage of megakaryocytic development. In the Tg mice, the recovery of platelet counts after antiplatelet serum-induced thrombocytopenia was not affected. In contrast, after 5-FU administration, we found a significant delay in platelet recovery in the Tg mice. These results led us to the hypothesis that Stat3 works mainly on the early stage of megakaryopoiesis and regulates the growth of megakaryocytic progenitor cells. Considering the previous reports that Stat3 is essential for the maintenance of embryonic stem cell pluripotency,36-38 Stat3 may function as an effector of expansion of the megakaryocytic progenitor cells. Previous studies indicate that TPO activates Stat3 and Stat5 in normal platelets.23 In addition, pretreatment of platelets with TPO enhances ADP-induced platelet aggregation.22 These findings led us to examine the platelet function of Tg mice. Although Stat3F proteins were abundantly expressed in the platelets of the Tg mice, platelet function was almost normal. There are 2 possible explanations for this discrepancy. One is that the Stat3 proteins in the platelets are just remnants of those in the megakaryocytes and do not have any function in the platelets. This notion is supported by evidence that platelets have no nuclei. The other possibility is that another signal transduction molecule rescued the function of Stat3. Considering that TPO activates Stat5 and Stat3 in normal megakaryocytes and platelets,14 Stat5 may be one of the candidates for compensating the function of Stat3 in ADP-induced platelet aggregation. However, because the expression and activation levels of Stat5 were not enhanced in the platelets of the Tg mice as they were in the control mice, it is unlikely that Stat5 rescued the function of Stat3. Therefore, taken together with the report by Yang et al39 that activation of Stat3 is insufficient for the priming effects of TPO on platelet aggregation, it is likely that Stat3 is dispensable for platelet function. In addition, the unprimed response to ADP (ie, in the absence of TPO) was greater in the Stat3F Tg mice than in the control mice (Figure 10). Although this was repeatable in 2 independent experiments, the detailed mechanism remains to be resolved. Although we did not identify the target genes for Stat3 in this study, one of the candidates of Stat3 may be c-myc gene. Several lines of evidence support this notion. First, the promoter region of the c-myc gene contains Stat3-binding sites, and IL-6 enhances c-myc gene promoter activity throughout Stat3 activation.40 Second, overexpression of the c-myc gene in megakaryocytic progenitors causes an increase in immature megakaryocytes.41 Third, we found that TPO-induced c-myc gene expression is dependent on Stat3 activation (unpublished data, March 4, 2002). Thus, c-myc may play an important role in cell expansion as a downstream molecule of Stat3,42 though this notion is speculative. In this study, we did not examine the expression of Stat3F in erythroid lineage cells. However, because the IE3.9int GATA-1 promoter works on megakaryocytic lineage cells and on erythroid lineage cells, it is strongly suggested that Stat3F is expressed in erythroid lineage cells. If so, given that the colony number of mature erythroid progenitor colony-forming units (CFU-E) was almost the same in the Tg mice and the control mice (data not shown), it is unlikely that Stat3 functions on late erythropoiesis. This result is consistent with previous findings that a dominant-negative Stat3 did not inhibit the erythroid colony formation from CFU-E in fetal liver cells.43 Interestingly, the number of immature erythroid progenitor blast-forming units was smaller in the Tg mice (data not shown), suggesting the possibility that Stat3 plays some role in early erythropoiesis. Unexpectedly, however, there was no significant difference between the Tg mice and the control mice in the recovery of hemoglobin level after 5-FU treatment (data not shown). Therefore, whether Stat3 is involved in erythropoiesis is still open to question. Although Stat3F completely inhibited tyrosine phosphorylation of endogenous Stat3 in the platelets of Stat3F Tg mice (Figure 2C), approximately half the Stat3 activity was still detected after transfection of UT-7/TPO cells with Stat3F (Figure 1A). Thus, there was a discrepancy in the Stat3F-induced inhibition of tyrosine phosphorylation and transcriptional activity of endogenous Stat3. Although we did not assess the DNA-binding activity of endogenous Stat3 in platelets of the Tg mice, one possibility is that the changes in phosphorylation were more pronounced than the changes in transcriptional activity of Stat3. This hypothesis may be supported by the previous report by Kaptein et al.44 Alternatively, the discrepancy may be attributed to the different cells used in these experiments. In conclusion, our observations showed that Stat3 is dispensable for steady-state megakaryopoiesis, maturation of megakaryocytes, and platelet function. However, our results suggest that Stat3 is required for effective expansion of megakaryocytic progenitor cells in the early stage of megakaryopoiesis.
Submitted December 17, 2001; accepted January 2, 2002.
Supported by Grants-in-Aid for Cancer Research and Scientific Research from the Ministry of Education, Science and Culture of Japan and by a grant from the Yamanouchi Foundation for Research on Metabolic Disorders.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Norio Komatsu, Division of Hematology, Department of Medicine, Jichi Medical School, Minamikawachi-machi, Kawachi-gun, Tochigi-ken 329-0498, Japan; e- mail: nkomatsu{at}ms.jichi.ac.jp.
1.
Kaushansky K.
Thrombopoietin: the primary regulator of platelet production.
Blood.
1995;86:419-431
2.
Kaushansky K.
Thrombopoietin.
N Engl J Med.
1998;339:746-754
3.
de Sauvage F, Carver-Moore K, Luoh SM, et al.
Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.
J Exp Med.
1996;183:651-656
4.
Weich N, Fitzgerald M, Wang A, et al.
Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro.
Blood.
2000;95:503-509
5.
Broudy V, Lin NL, Kaushansky K.
Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.
Blood.
1995;85:1719-1726 6. Ihle JN, Thierfelder W, Teglund S, et al. Signaling by the cytokine receptor superfamily. Ann N Y Acad Sci. 1998;865:1-9[CrossRef][Medline] [Order article via Infotrieve].
7.
Rojnuckarin P, Drachman JG, Kaushansky K.
Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis.
Blood.
1999;94:1273-1282
8.
Rojnuckarin P, Kaushansky K.
Actin reorganization and proplatelet formation in murine megakaryocytes: the role of protein kinase c alpha.
Blood.
2001;97:154-161
9.
Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K.
Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes.
J Biol Chem.
2001;276:2494-2502
10.
Drachman J, Millett KM, Kaushansky K.
Thrombopoietin signal transduction requires functional JAK2, not TYK2.
J Biol Chem.
1999;274:13480-13484
11.
Komatsu N, Kunitama M, Yamada M, et al.
Establishment and characterization of the thrombopoietin-dependent megakaryocytic cell line, UT-7/TPO.
Blood.
1996;87:4552-4560 12. Kunitama M, Shimizu R, Yamada M, et al. Protein kinase C and c-myc gene activation pathways in thrombopoietin signal transduction. Biochem Biophys Res Commun. 1997;231:290-294[CrossRef][Medline] [Order article via Infotrieve]. 13. Yamada M, Komatsu N, Okada K, et al. Thrombopoietin induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in a human thrombopoietin-dependent cell line. Biochem Biophys Res Commun. 1995;217:230-237[CrossRef][Medline] [Order article via Infotrieve].
14.
Drachman JG, Sabath DF, Fox NE, Kaushansky K.
Thrombopoietin signal transduction in purified murine megakaryocytes.
Blood.
1997;89:483-492
15.
Weich N, Wang A, Fitzgerald M, et al.
Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro.
Blood.
1997;90:3893-3902
16.
Takeda K, Noguchi K, Shi W, et al.
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality.
Proc Natl Acad Sci U S A.
1997;94:3801-3804 17. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene. 2000;19:2607-2611[CrossRef][Medline] [Order article via Infotrieve].
18.
Takeda K, Kaisho T, Yoshida N, et al.
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice.
J Immunol.
1998;161:4652-4660 19. Martin D, Zon LI, Mutter G, Orkin SH. Expression of an erythroid transcription factor in megakaryocytic and mast cell lineages. Nature. 1990;344:444-447[CrossRef][Medline] [Order article via Infotrieve]. 20. Romeo P, Prandini MH, Joulin V, et al. Megakaryocytic and erythrocytic lineages share specific transcription factors. Nature. 1990;344:447-449[CrossRef][Medline] [Order article via Infotrieve].
21.
Takahashi S, Shimizu R, Suwabe N, et al.
GATA factor transgenes under GATA-1 locus control rescue germline GATA-1 mutant deficiencies.
Blood.
2000;96:910-916
22.
Oda A, Miyakawa Y, Druker B, et al.
Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists.
Blood.
1996;87:4664-4670
23.
Miyakawa Y, Oda A, Druker B, et al.
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets.
Blood.
1996;87:439-446
24.
Jackson CW.
Cholinesterase as a possible marker for early cells of the megakaryocytic series.
Blood.
1973;42:413-421
25.
Shibuya K, Akahori H, Takahashi K, et al.
Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
Blood.
1998;91:37-45 26. Kabaya K, Akahori H, Shibuya K, et al. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice. Stem Cells. 1996;14:651-660[Medline] [Order article via Infotrieve]. 27. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15:3651-3658[Medline] [Order article via Infotrieve].
28.
Kirito K, Uchida M, Takatoku M, et al.
A novel function of Stat1 and Stat3 proteins in erythropoietin-induced erythroid differentiation of a human leukemia cell line.
Blood.
1998;92:462-471
29.
Onodera K, Takahashi S, Nishimura S, et al.
GATA-1 transcription is controlled by distinct regulatory mechanisms during primitive and definitive erythropoiesis.
Proc Natl Acad Sci U S A.
1997;94:4487-4492
30.
Nandurkar H, Robb L, Tarlinton D, et al.
Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis.
Blood.
1997;90:2148-2159
31.
Radley J, Hodgson GS, Levin J.
Platelet production after administration of antiplatelet serum and 5-fluorouracil.
Blood.
1980;55:164-166
32.
Chenaille P, Steward SA, Ashmun RA, Jackson CW.
Prolonged thrombocytosis in mice after 5-fluorouracil results from failure to down-regulate megakaryocyte concentration: an experimental model that dissociates regulation of megakaryocyte size and DNA content from megakaryocyte concentration.
Blood.
1990;76:508-515
33.
Arnold JT, Daw NC, Stenberg PE, Jayawardene D, Srivastava DK, Jackson CW.
A single injection of pegylated murine megakaryocyte growth and development factor (MGDF) into mice is sufficient to produce a profound stimulation of megakaryocyte frequency, size, and ploidization.
Blood.
1997;89:823-833
34.
Ulich TR, del Castillo J, Senaldi G, et al.
Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice.
Blood.
1996;87:5006-5015
35.
Luoh SM, Stefanich E, Solar G, et al.
Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo.
Mol Cell Biol.
2000;20:507-515
36.
Niwa H, Burdon T, Chambers I, Smith A.
Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3.
Genes Dev.
1998;12:2048-2060 37. Matsuda T, Nakamura T, Nakao K, et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999;18:4261-4269[CrossRef][Medline] [Order article via Infotrieve].
38.
Raz R, Lee CK, Cannizzaro LA, d'Eustachio P, Levy DE.
Essential role of STAT3 for embryonic stem cell pluripotency.
Proc Natl Acad Sci U S A.
1999;96:2846-2851
39.
Yang F, Tsuji K, Oda A, et al.
Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice.
Blood.
1999;94:950-958
40.
Kiuchi N, Nakajima K, Ichiba M, et al.
STAT3 is required for the gp130-mediated full activation of the c-myc gene.
J Exp Med.
1999;189:63-73
41.
Thompson A, Zhang Y, Kamen D, et al.
Deregulated expression of c-myc in megakaryocytes of Tg mice increases megakaryopoiesis and decreases polyploidization.
J Biol Chem.
1996;271:22976-22982
42.
Schmid P, Schulz WA, Hameister H.
Dynamic expression pattern of the myc protooncogene in midgestation mouse embryos.
Science.
1989;243:226-229
43.
Chida D, Miura O, Yoshimura A, Miyajima A.
Role of cytokine signaling molecules in erythroid differentiation of mouse fetal liver hematopoietic cells: functional analysis of signaling molecules by retrovirus-mediated expression.
Blood.
1999;93:1567-1578
44.
Kaptein A, Paillard V, Saunders M.
Dominant negative Stat3 mutant inhibits interleukin-6-induced Jak-Stat signaling transduction.
J Biol Chem.
1996;271:5961-5964
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. I. Fortoul, A. Gonzalez-Villalva, G. Pinon-Zarate, V. Rodriguez-Lara, L. F. Montano, and L. Saldivar-Osorio Ultrastructural megakaryocyte modifications after vanadium inhalation in spleen and bone marrow J. Electron Microsc. (Tokyo), December 1, 2009; 58(6): 375 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhiyi, L. Wenshan, Z. Wenze, D. Ning, Z. Chi, Y. Kenan, W. Ping, W. Qianqian, and Z. Qing Secretion Expression and Activity Assay of a Novel Fusion Protein of Thrombopoietin and Interleukin-6 in Pichia pastoris J. Biochem., July 1, 2007; 142(1): 17 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Teofili, M. Martini, T. Cenci, G. Petrucci, L. Torti, S. Storti, F. Guidi, G. Leone, and L. M. Larocca Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation Blood, July 1, 2007; 110(1): 354 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Raslova, V. Baccini, L. Loussaief, B. Comba, J. Larghero, N. Debili, and W. Vainchenker Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation Blood, March 15, 2006; 107(6): 2303 - 2310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, P. Paradis, A. Aries, H. Komati, C. Lefebvre, H. Wang, and M. Nemer Convergence of Protein Kinase C and JAK-STAT Signaling on Transcription Factor GATA-4 Mol. Cell. Biol., November 15, 2005; 25(22): 9829 - 9844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezoe, I. Matsumura, K. Gale, Y. Satoh, J. Ishikawa, M. Mizuki, S. Takahashi, N. Minegishi, K. Nakajima, M. Yamamoto, et al. GATA Transcription Factors Inhibit Cytokine-dependent Growth and Survival of a Hematopoietic Cell Line through the Inhibition of STAT3 Activity J. Biol. Chem., April 1, 2005; 280(13): 13163 - 13170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Tong and H. F. Lodish Lnk Inhibits Tpo-mpl Signaling and Tpo-mediated Megakaryocytopoiesis J. Exp. Med., September 7, 2004; 200(5): 569 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Suzuki, N. Suwabe, O. Ohneda, N. Obara, S. Imagawa, X. Pan, H. Motohashi, and M. Yamamoto Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels Blood, November 15, 2003; 102(10): 3575 - 3583. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1, phosphatidylinositol 3-kinase-Akt, RAS-mitogen-activated protein kinase (MAPK), and Janus
tyrosine kinase-signal transducer and activator of transcription (Stat)
activation pathways.
) and 2 lines of
Stat3F expressing UT-TPO cells (clone 1, 
; clone 2, 
) were
cultured with 10 ng/mL TPO for the indicated periods. Cell numbers and
viability were assessed by trypan blue dye exclusion.
, Tg
mice).
